Toshimitsu Yamaoka
Hatanodai, 1428555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis.
Journal: International journal of molecular sciences
Published: December 23, 2022
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.
Journal: Cells
Published: May 26, 2022
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: January 08, 2021
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Journal: International journal of molecular sciences
Published: December 23, 2020
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.
Journal: Translational lung cancer research
Published: November 19, 2020
Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells.
Journal: Antibodies (Basel, Switzerland)
Published: October 28, 2020
Last Updated: 09/26/2026